03 Feb 2026 Avacta announces two key clinical updates to its faridoxorubicin program Investors | Therapeutics
21 Jan 2026 Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103) Investors | Therapeutics
18 Dec 2025 Research & Development Spotlight Series, Episode 13 Podcasts and Videos | R&D Spotlights Series | Therapeutics
17 Dec 2025 Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Investors | Therapeutics
08 Dec 2025 Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort Investors | Therapeutics
25 Oct 2025 Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets Investors | Therapeutics
21 Oct 2025 ESMO Phase 1a data for faridoxorubicin presented by Chris Coughlin and David Liebowitz Podcasts and Videos | Therapeutics